Monopar Therapeutics Inc. – Consensus Indicates Potential 437.8% Upside

Broker Ratings

Monopar Therapeutics Inc. with ticker code (MNPR) have now 3 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 40 and 11 with a mean TP of 30.33. With the stocks previous close at 5.64 this now indicates there is a potential upside of 437.8%. The 50 day MA is 5.06 and the 200 day moving average is 6.05. The market cap for the company is $69m. Company Website: http://www.monopartx.com

Monopar Therapeutics Inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase III for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and MNPR-101, a humanized monoclonal antibody for treating advanced solid cancers. The company has a collaboration Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp

AIM All Share Index